Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.33
>-AU$0.01(-2.22%)
At close: 4:00 PM EST
AU$0.33
>-AU$0.01(-2.22%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.46
Previous CloseN/A
Volume11.90M
Average Volume (3M)877.83K
Market Cap
AU$56.14M
Enterprise ValueAU$31.22M
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-24.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$2.50M
Bulls Say, Bears Say
Bulls Say
Diverse Immuno-oncology PipelineImugene's multi-modal clinical pipeline spreads scientific and regulatory risk across distinct immuno-oncology approaches. That diversity creates multiple durable value inflection points (clinical readouts, partnerships) over 2-6 months plus, increasing chances of a de-risking event.
Conservative Capital Structure (low Leverage)A low debt-to-equity ratio indicates limited financial leverage, reducing short-term solvency risk and offering flexibility to fund R&D or endure trial timelines. This conservatism supports durability of operations while clinical programs progress toward milestones.
Pipeline Can Enable Partnership/licensing RevenueThe company’s explicit pathway to revenue via partnering or licensing is a structural strength: successful clinical progress can unlock non-dilutive upfronts, milestones and royalties, providing sustainable funding alternatives to sole commercialization efforts.
Bears Say
Severe Revenue ContractionA dramatic revenue decline signals the absence of sustainable commercial income and heightens dependency on external financing. Over months this undermines self-funding of trials, weakens negotiating leverage with partners, and increases execution risk for programs.
Negative Operating Cash FlowPersistent negative operating cash flow indicates the business is consuming cash to run R&D and operations. This structural cash burn forces recurring fundraising, constrains strategic flexibility, and can delay or curtail development programs if financing becomes limited.
Reliance On Equity FinancingDependence on equity raises creates ongoing dilution risk and financing uncertainty. Over a 2-6 month horizon this can pressure program continuity, governance dynamics, and shareholder returns if clinical milestones needed to attract partners or non-dilutive funding are not met.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.09 and its highest was AU$0.46 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$56.14M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 61 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 415,835,050 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-24.24% Downside)
AU$0.25 (-24.24% Downside)
Blogger Sentiment
Neutral
AU:IMU Sentiment 59%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$89.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-24.24% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---